-
Study aim
-
To evaluate the efficacy of zinc supplementation compared to a placebo in augmenting standard therapy for the management of bronchiolitis in pediatric patients.
-
Design
-
Single blind randomized controlled trial
-
Settings and conduct
-
The study was conducted in the patients admitted in Children hospital and university of child health sciences
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria
Children with age group 2 - 23 months having and Clinical signs & symptoms of acute bronchiolitis were included
Exclusion criteria
Children with use of mechanical ventilation in neonates or History of prematurity, Recent use of antibiotic, Congenital heart and lung disease, Down syndrome, Respiratory failure signs, Immunodeficiency, Previous wheezing episodes history, Family history of allergies and/or asthma, Metabolic or neurological diseases, Zinc intake during the previous one month were excluded
-
Intervention groups
-
One group received 1% zinc sulphate (20mg/5ml) orally (0.5 cc/kg in children with age below one year and 5cc (20 mg) in children with age above 1 year). Other group received placebo treatment (5%-100% glucose water and oral flavoring). General appearance, smell, color and taste of the Zinc and placebo syrups was similar.
-
Main outcome variables
-
Patients were evaluated for the clinical sign & symptoms including wheezing, rhinorrhea, cyanosis, subcostal and intercostal retraction, tachypnea, fever and nasal flaring. pre-designed Performa was sued to record findings.